Compare Paycom Software Inc (PAYC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Sana Biotechnology Inc — how do they compare? Paycom Software Inc trades at $231.94 (market cap $10.36B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Paycom Software Inc is far larger — about 12.4× Sana Biotechnology Inc's market cap, and Paycom Software Inc pays a 0.65% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and Sana Biotechnology Inc for 23 Days on average.
| PAYC | SANA | |
|---|---|---|
Market Cap | $10.36B | $836.71M |
Volume | 666,294 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $240.52 | $5.92 |
52-Week Low | $113.59 | $2.68 |
Typical Hold Time | 84 Days | 23 Days |
Enterprise Value | $11.15B | $749.96M |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $232.22, up 3.86% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The stock shows bullish technical signals, with support near $226 and resistance at $232. Fundamentally, PAYC maintains robust profitability with a 22.78% net margin and 10% revenue growth in Q2 2026, though its P/E of 24.33 suggests a premium valuation. Positive sentiment is driven by institutional buying and analyst coverage, with 47% recommending Buy.
Outlook: PAYC's earnings momentum and operational efficiency support upside, but risks include premium valuation pressure and labor market sensitivity. The consensus price target of $207.75 implies caution, yet raised guidance and buybacks provide tailwinds. Investors should weigh strong execution against macroeconomic headwinds affecting payroll demand.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
